← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 1998First marketed drug
May 21, 2002First NDA
May 21, 2002Last known activity
Jul 31, 2026
Timeline
1990s
- Jan 1, 1996
United Therapeutics— Founded
- Oct 1, 1999
SynQuest— Acquired
2000s
- Dec 1, 2000
Medicomp— Acquired
2010s
- Mar 10, 2015
dinutuximab— Marketing Organization
- Mar 10, 2015
dinutuximab— NDA Organization
Drugs by trial phase (30 distinct, 93 trials)
Phase 4 (5 own, 4 via acquisition)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (11 own, 0 via acquisition)
Phase 1 (7 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Lung Injury
- Anemia, Sickle Cell
- Bronchopulmonary Dysplasia
- Calcinosis
- Cardiovascular Diseases
- Connective Tissue Diseases
- Delayed Graft Function
- Emphysema
- Familial Primary Pulmonary Hypertension
- Fibrosis
- Foot Ulcer
- Heart Failure
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hypertension
- Hypertension, Pulmonary
- Idiopathic Pulmonary Fibrosis
- Ischemia
- Lung Diseases
- Lung Diseases, Interstitial
- Lung Diseases, Obstructive
- Lung Neoplasms
- Neuroblastoma
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Persistent Fetal Circulation Syndrome
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Fibrosis
- Raynaud Disease
- Renal Insufficiency
- Reperfusion Injury
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Respiratory Tract Diseases
- Sarcoidosis
- Scleroderma, Diffuse
- Scleroderma, Localized
- Scleroderma, Systemic
- Sclerosis
- Small Cell Lung Carcinoma
- Vascular Diseases
- Wounds and Injuries
Marketed drugs (2)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT07261241CollaboratorPhase 2Jul 31, 2026
- NCT07116681CollaboratorEarly Phase 1Oct 1, 2025
- NCT07037836CollaboratorPhase 2Sep 29, 2025
- NCT06450041CollaboratorPhase 2Nov 30, 2024
- NCT05943535Lead sponsorPhase 3Oct 30, 2023
- NCT05564637CollaboratorPhase 2Nov 30, 2022
- NCT05255991Lead sponsorPhase 3Oct 4, 2022
- NCT05203510Lead sponsorPhase 4Aug 10, 2022
- NCT05421897CollaboratorPhase 4Jul 31, 2022
- NCT04905693Lead sponsorPhase 3May 31, 2022
- NCT04708782Lead sponsorPhase 3Jun 1, 2021
- NCT04084678Lead sponsorPhase 3Dec 15, 2019
- NCT04084678Study directorPhase 3Dec 15, 2019
- NCT03814317CollaboratorPhase 2Sep 30, 2019
- NCT03950739Study directorPhase 1Aug 31, 2019
Details
- Founded
- Silver Spring, MD, US Jan 1, 1996
- First NDA
- May 21, 2002
- Last known activity
- Jul 31, 2026
Designations held
- Orphan drug
- Priority review
- Accelerated approval